Omeza Raises $8.5 Million in Series A Funding
Sarasota, Florida-based Omeza, a company leveraging marine science to address chronic wound issues, has successfully secured $8.5 million in a Series A funding round. This round was led by Astanor and BluKap Ventures, with additional participation from Catalyst Investments and the Florida Opportunity Fund.
Investment Details
The Series A round, which was finalized on April 22, 2026, marks a significant milestone for Omeza as it seeks to expand its innovative solutions for managing chronic wounds. The funding will provide the company with the necessary resources to enhance its product offerings and potentially explore new market opportunities.
Lead Investors
Astanor and BluKap Ventures spearheaded the investment, bringing their expertise and resources to support Omeza's growth. The participation of Catalyst Investments and the Florida Opportunity Fund further underscores the confidence investors have in Omeza's potential to make a meaningful impact in the healthcare sector.
Use of Funds
While specific details on the use of funds were not disclosed, it is expected that Omeza will allocate the capital towards expanding its research and development capabilities, enhancing its product portfolio, and possibly increasing its market presence. The infusion of funds could also support strategic hires to bolster the company's expertise and operational capacity.
About Omeza
Omeza's work is rooted in marine science, focusing on developing solutions to common issues associated with chronic wounds. By applying scientific principles and research, the company aims to improve patient outcomes and provide effective treatments for long-standing wound care challenges.
This funding round positions Omeza to further its mission and continue its efforts in addressing the often-overlooked needs of patients dealing with chronic wounds.